Chiasma (NASDAQ:CHMA) Lowered to Hold at Zacks Investment Research

Share on StockTwits

Zacks Investment Research cut shares of Chiasma (NASDAQ:CHMA) from a buy rating to a hold rating in a report issued on Wednesday, Zacks.com reports.

According to Zacks, “Chiasma, Inc. is a biopharmaceutical company. The company’s TPE(R) technology develops oral peptides and other molecules. Its primary product candidate consists of oral octreotide which is in different clinical trial. Chiasma, Inc. is based in Newton, USA. “

CHMA has been the subject of several other research reports. Cantor Fitzgerald set a $18.00 price objective on Chiasma and gave the company a buy rating in a report on Friday, June 28th. HC Wainwright lowered Hydrogenics from a buy rating to a neutral rating in a report on Friday, June 28th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The stock currently has an average rating of Buy and a consensus target price of $12.94.

Shares of CHMA stock opened at $6.44 on Wednesday. Chiasma has a 1 year low of $1.20 and a 1 year high of $8.29. The stock’s fifty day simple moving average is $7.40.

Chiasma (NASDAQ:CHMA) last announced its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.34) by ($0.02). Sell-side analysts expect that Chiasma will post -1.14 earnings per share for the current fiscal year.

In other news, Director Roni Mamluk sold 10,000 shares of the company’s stock in a transaction on Tuesday, April 16th. The stock was sold at an average price of $5.31, for a total value of $53,100.00. Following the completion of the sale, the director now owns 10,000 shares in the company, valued at $53,100. The sale was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 6.20% of the company’s stock.

Several institutional investors have recently made changes to their positions in CHMA. New Leaf Venture Partners L.L.C. acquired a new stake in shares of Chiasma in the first quarter valued at $2,080,000. Tibra Equities Europe Ltd acquired a new stake in shares of Chiasma during the first quarter worth $200,000. Deutsche Bank AG raised its position in shares of Chiasma by 27.8% during the fourth quarter. Deutsche Bank AG now owns 78,198 shares of the biotechnology company’s stock worth $243,000 after purchasing an additional 16,996 shares during the period. Dimensional Fund Advisors LP raised its position in shares of Chiasma by 20.6% during the fourth quarter. Dimensional Fund Advisors LP now owns 97,644 shares of the biotechnology company’s stock worth $304,000 after purchasing an additional 16,658 shares during the period. Finally, Millennium Management LLC acquired a new stake in shares of Chiasma during the fourth quarter worth $41,000. Institutional investors and hedge funds own 62.78% of the company’s stock.

Chiasma Company Profile

Chiasma, Inc, a clinical-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease in the United States, Europe, and internationally. The company offers oral octreotide capsules for adult patients under the MYCAPSSA name, which is in two Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone.

Further Reading: Bear Market – How and Why They Occur

Get a free copy of the Zacks research report on Chiasma (CHMA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Chiasma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply